Navigation Links
Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Date:3/3/2011

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce fourth quarter and year ended December 31, 2010 financial results on Thursday, March 10, 2011 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 788-0543 (domestic) or (857) 350-1681 (international), participant code 73770341. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com  and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response Letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
3. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
4. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
5. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
6. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
7. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
10. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
11. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... 22, 2015  ResMed Inc. (NYSE: RMD ) today ... for the quarter was $423.0 million, a 10 percent increase ... percent increase on a constant currency basis). Net income was ... quarter ended December 31, 2013. Diluted earnings per share for ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical ... diabetes and obesity, announced today a new textbook,  Translational ... published by Springer, a leading global scientific publisher. ... and illustrate techniques for use in early phase clinical ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... MiMedx Group, Inc. (OTC Bulletin Board: MDXG ... protected biomaterial-based products, announced today that it has received ... product using the Company,s proprietary HydroFix™ technology. ... is in addition to the Company,s previous certification for ...
... Dey Pharma, L.P. today announced that it has signed ... pharma company headquartered in Sweden, for the exclusive marketing ... EpiPen Auto-Injector is used for emergency treatment of severe ... a couple of minutes, and may be life-threatening. ...
Cached Medicine Technology:MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 2MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 3MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 4Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 2Mylan's Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe 3
(Date:1/22/2015)... January 22, 2015 Deer Path of Huntley ... a Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. ... Regency Parkway in Huntley, Illinois, serves adults with physical disabilities between ... will include Valentine's Day treats, games and sweetheart-themed karaoke. , For ...
(Date:1/22/2015)... 22, 2015 Liberty University has received accreditation ... program from the Council for Accreditation of Counseling & ... Liberty’s Center for Counseling & Family Studies , is ... the university’s new School of Behavioral Sciences. Prior to the ...
(Date:1/22/2015)... The City of West Hollywood hosted a news ... the 42nd anniversary of the Supreme Court decision Roe v. Wade, ... years since the Roe vs. Wade decision and the fight to ... ever,” said City of West Hollywood Councilmember Abbe Land. “We need ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... retention, organizational relationships citedGAITHERSBURG, Md., April 20 ... facilities management services company, was named second ... for Latinos list, based on measurements of ... corporate/organizational communications from more than 400 applicants.Ricardo ...
... The Brooklyn Autism Center (BAC) is a not-for-profit, ... The program was founded by parents, educators and ... quality, effective educational services for children on the ... to: http://www.prnewswire.com/mnr/brooklynautismcenter/37761/ BAC offers outreach resources ...
... ORLANDO, Fla. , April 20 ... with the March of Dimes Florida Chapter ... its March for Babies events on April 25. Additionally, ... either a Bachelor of Science in Nursing or a Master ...
... Dr. Maureen Storey, senior vice president of science policy ... her new analysis indicating that consumers of all ages ... years ago. The data are from the Centers ... Examination Survey (NHANES) the largest and longest-running national, ...
... quarter of people with alcohol-related cirrhosis die before they ... silently but usually presents with an episode of internal ... The study, led by Dr Nick Sheron, senior lecturer ... Southampton General Hospital, found that abstinence from alcohol is ...
... Providers Able To Transmit Electronic Claims Through Availity ... LLC, the industry,s premier health information network, today ... designated electronic claims clearinghouse by Mid Rogue Health ... located in Grants Pass, Oregon. After a successful ...
Cached Medicine News:Health News:Sodexo Ranks Second on the 2009 DiversityInc Top Ten Companies for Latinos List 2Health News:Sodexo Ranks Second on the 2009 DiversityInc Top Ten Companies for Latinos List 3Health News:Photos: Questions About Autism? The Brooklyn Autism Center Academy Can Help. 2Health News:Photos: Questions About Autism? The Brooklyn Autism Center Academy Can Help. 3Health News:University of Phoenix Announces March of Dimes Partnership in Florida, Offers Four Full-Tuition Nursing Scholarships 2Health News:University of Phoenix Announces March of Dimes Partnership in Florida, Offers Four Full-Tuition Nursing Scholarships 3Health News:Consumers respond to lower calorie beverage options 2Health News:New study finds continued abstinence is key to increased survival from alcohol-related liver disease 2Health News:Mid Rogue Health Plan Implements Availity as Its Designated Clearinghouse 2
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ester ... by enzymatic conversion of DHEA in adrenal ... C19 steroid secreted by the adrenal cortex, ... estrogen biosynthesis. DHEA possesses relatively weak androgenic ...
Inquire...
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
RFScan Latex Test Kit-100...
Medicine Products: